Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy

Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy has achieved 40 %-50 % long-term complete response in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients. However, the underlying mechanism of alterations in the tumor microenvironments resulting in CAR-T cell therapy failur...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Frontiers of medicine 2023-08, Vol.17 (4), p.699-713
Hauptverfasser:	Yan, Zixun, Li, Li, Fu, Di, Wu, Wen, Qiao, Niu, Huang, Yaohui, Jiang, Lu, Wu, Depei, Hu, Yu, Zhang, Huilai, Xu, Pengpeng, Cheng, Shu, Wang, Li, Lacin, Sahin, Muftuoglu, Muharrem, Zhao, Weili
Format:	Artikel
Sprache:	eng
Schlagworte:	anti-CD19 chimeric antigen receptor T Antigens diffuse large B cell lymphoma immunotherapy Lymphocytes Lymphoma Medicine Medicine & Public Health Metabolism Remission (Medicine) Research Article tumor microenvironment tumor-associated macrophage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!